Sharing is caring!

Burosumab Brand Name– CRYSViTA

What is Burosumab

Burosumab is a fibroblast growth factor 23 (FGF23) blocking antibody. It is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older.

Burosumab is also indicated for the treatment of tumor-induced osteomalacia (TIO) in adult and pediatric patients 2 years of age and older.

In a placebo-controlled study involving 134 adult patients with XLH, 94% of adults receiving burosumab once a month achieved normal phosphorus concentrations compared to 8% of those receiving placebo.

In pediatric studies, 94% to 100% of patients treated with burosumab every 2 weeks achieved normal phosphorus concentrations. Additionally, there was an improvement in X-ray findings associated with XLH in both children and adults receiving burosumab therapy.

In 2 single-arm, phase 2 trials (n = 14 and n = 13), the mean serum phosphorus levels increased to above the lower limit of normal (LLN) following 24 weeks of burosumab therapy in 50% and 69% of adult patients with TIO.

The safety and efficacy of burosumab in pediatric patients 2 years and older with TIO were extrapolated from adult TIO study data and study and pharmacokinetic data in adults and pediatric patients with XLH.

The use of oral phosphate and active vitamin D analogs is contraindicated during burosumab treatment; discontinue these products 1 week prior to the initiation of burosumab.

Ensure serum phosphorous concentrations are below the reference range for age prior to treatment initiation; monitor serum phosphorus monthly for the first 3 months of treatment and periodically thereafter.


  • hypophosphatemia
  • osteomalacia

Side Effects

  1. antibody formation
  2. back pain
  3. constipation
  4. cough
  5. dental caries
  6. dental pain
  7. diarrhea
  8. dizziness
  9. fever
  10. headache
  11. hyperphosphatemia
  12. infection
  13. injection site reaction
  14. maculopapular rash
  15. muscle cramps
  16. myalgia
  17. nausea
  18. rash
  19. restless legs syndrome (RLS)
  20. spinal cord compression
  21. urticaria
  22. vitamin D deficiency
  23. vomiting

Monitoring Parameters

  • serum phosphate


  • breast-feeding
  • hyperphosphatemia
  • pregnancy
  • radiation therapy
  • renal failure
  • renal impairment
  • surgery


  • Calcifediol
  • Calcitriol
  • Calcium Phosphate, Supersaturated
  • Dihydrotachysterol
  • Doxercalciferol
  • Erdafitinib
  • Ibritumomab Tiuxetan
  • Paricalcitol
  • Potassium Phosphate
  • Potassium Phosphate; Sodium Phosphate
  • Sodium Phosphate Monobasic Monohydrate; Sodium Phosphate Dibasic Anhydrous
  • Vitamin D analogs

Sharing is caring!


Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

Scroll to Top